Skip to main content
. 2014 Jun 27;9(6):e100281. doi: 10.1371/journal.pone.0100281

Figure 5. Effects of chronic clenbuterol treatment on EDL muscle calpain activity.

Figure 5

A, Calpain activity was determined in whole EDL muscle homogenates using a calpain-specific fluorogenic substrate in control (CTR) and clenbuterol-treated (CLB) animals. * p<0.05 compared to controls. B, Western blot analysis with polyclonal anti-calpain 1 and polyclonal anti-calpain 2 antibodies of EDL muscle homogenates from control (CTR) and clenbuterol-treated (CLB) animals. C, Calculation of the calpain fractional activation index (i.e., percentage of autolysed calpains) in EDL muscle homogenates from control (CTR) and clenbuterol treated (CLB) animals. Values are the mean ± SEM of 8 animals in each group. * p<0.05 compared to controls.